Clinical trials: Other
Low Anterior Resection Syndrome, Malignant Anal Neoplasm
Sacral Nerve Stimulation in Treating Low Anterior Resection Syndrome or Fecal Incontinence in Patients With Locally Advanced Rectal Cancer or Other Pelvic Cancer, the RESTORE Study
This phase II trial studies how well sacral nerve stimulation works in treating low anterior resection syndrome or fecal incontinence (the body's passage of stool without control) in patients with rectal cancer that has spread to…
- Conditions
- Low Anterior Resection Syndrome, Malignant Anal Neoplasm, Malignant Bladder Neoplasm, Malignant Cervical Neoplasm
- Trial name
- NCT04066894
- Testing
- Explantation, Quality-of-Life Assessment, Questionnaire Administration
- Where
- 2 sites in United States
- Volunteers
- 3 people
- Sponsor
- M.D. Anderson Cancer Center
Neoplasms, Pancreatic
First-time-in-human (FTIH) Study of GSK3145095 Alone and in Combination With Other Anticancer Agents in Adults With Advanced Solid Tumors
In an unbiased CRISPR screen, RIPK1 was identified as a top gene contributing to immunotherapy resistance. In addition, RIPK1 has been reported to drive pancreatic oncogenesis.
- Trial name
- NCT03681951
- Testing
- GSK3145095, Pembrolizumab
- Where
- 6 sites in United States
- Volunteers
- 8 people
- Sponsor
- GlaxoSmithKline
Schizophrenia, Schizoaffective Disorder
Comparing the Effect of Under the Tongue Olanzapine Versus Swallowed Olanzapine on Body Mass Index (A Ratio of Weight to Height)
This study is testing if under the tongue olanzapine for schizophrenia, related psychosis, schizoaffective disorder or bipolar disorder will have less weight gain than olanzapine that is swallowed, in patients who are already…
- Conditions
- Schizophrenia, Schizoaffective Disorder, Bipolar Disorder
- Trial name
- NCT00303602
- Testing
- Sublingual orally disintegrating olanzapine (SODO), Oral olanzapine
- Where
- 21 sites in United States, Canada and 3 more
- Volunteers
- 149 people
- Sponsor
- Eli Lilly and Company
Paranoid Schizophrenia
MK0249 for the Treatment of Cognitive Impairment in Patients With Schizophrenia (0249-016)
The purpose of this study is to determine the safety and effectiveness of an investigational drug MK0249 for the treatment of the cognitive impairment in patients with schizophrenia.
- Trial name
- NCT00506077
- Testing
- MK0249
- Volunteers
- 55 people
- Sponsor
- Merck Sharp & Dohme LLC
Schizophrenia
A Multicenter Study of NAP (AL-108) in Schizophrenia
The TURNS is a NIMH-funded contract for the evaluation of new compounds for the treatment of cognitive impairments in schizophrenia (HHSN 27820044 1003C; P.I.: Steve Marder, M.D.).
- Trial name
- AL-108 (NCT00505765)
- Testing
- AL-108
- Where
- 8 sites in United States
- Volunteers
- 63 people
- Sponsor
- University of California, Los Angeles
Severe Forms of Hemophilia, Other Constitutional Bleeding Disorders
Input of a Multidisciplinary Device to Accompany the Announce of Diagnosis for Young Children With Serious Constitutional Hemorrhagic Disease and Their Families
Severe forms of hemophilia and other constitutional bleeding disorders represent a group of rare diseases. In last decades, news therapies have dramatically increased life expectancy and joint's protection.
- Trial name
- ACADHEM (NCT02834130)
- Testing
- Evaluation of psychological and psychopathological
- Where
- France
- Volunteers
- 30 people
- Sponsor
- Assistance Publique Hopitaux De Marseille
Other Abnormal Uterine and Vaginal Bleeding
Permanent Occlusion of Uteine Arteies in Management of Abnormal Uterine Bleeding
Prospective observational interventional study , The study done in two phases: 1. Phase one from October 2011to May 2012 pilot study including twenty nine (29) premenopausal patients followed up for six months 2.
- Trial name
- NCT05423067
- Testing
- bilateral permanent occlusion of uterine arteries
- Where
- Egypt
- Volunteers
- 116 people
- Sponsor
- Mansoura Integrated Fertility Center
MPS IV A
A Double-Blind Study to Evaluate the Efficacy and Safety of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome)
This Phase 3 study will evaluate the efficacy and safety of 2.0 mg/kg/week BMN 110 and 2.0 mg/kg/every other week BMN 110 in patients with mucopolysaccharidosis IVA (Morquio A Syndrome).
- Trial name
- NCT01275066
- Testing
- BMN 110 Weekly, BMN 110 Every Other Week
- Where
- 28 sites in United States, Argentina and 15 more
- Volunteers
- 177 people
- Sponsor
- BioMarin Pharmaceutical
Schizophrenia, Schizoaffective Disorder
Enhancing Motivation To Quit Smoking In Smokers With Serious Mental Illness
This project will assess the utility of a brief motivational intervention to engage smokers with schizophrenia in treatment for tobacco dependence treatment.
- Trial name
- NCT00500695
- Testing
- Motivational Interviewing, Psychoeducation
- Where
- United States
- Volunteers
- 98 people
- Sponsor
- Rutgers, The State University of New Jersey
Schizophrenia
Clinical Intervention on Cognitive Impairment of Schizophrenia With Metabolic Syndrome
This is a single-center, randomized, parallel-control study conducted in schizophrenic inpatients with metabolic syndrome who have been conducted with olanzapine.
- Trial name
- NCT04518319
- Testing
- Omega-3 polyunsaturated fatty acids, Xbox aerobic exercise, transcranial direct current stimulation,tDCS
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Shanghai Mental Health Center
Mild Cognitive Disorder, Alzheimer Disease
Digital Dementia Registry Bavaria (digiDEM Bayern): a Multicentre, Prospective, Longitudinal Register Study Including People With Mild Cognitive Impairment and Dementia as Well as Their Family Caregivers
Around 57 million people worldwide live with dementia, with approximately 10 million new cases diagnosed each year. By the end of 2023, around 1.8 million people were living with dementia in Germany, the majority of whom were…
- Conditions
- Mild Cognitive Disorder, Alzheimer Disease, Vascular Dementia, Dementia in Other Diseases Classified Elsewhere
- Trial name
- digiDEM Bayern (NCT07721701)
- Where
- 12 sites in Germany
- Volunteers
- 5,000 people
- Sponsor
- University of Erlangen-Nürnberg Medical School
Schizophrenia
The Effect of Sertindole and Risperidone on Endophenotypic Markers of Schizophrenia
This comparison is made between the effects of sertindole and risperidone on vulnerability indicators in schizophrenia. More specifically: the effects of these two antipsychotic compounds on basic processing of incoming…
- Trial name
- NCT02021201
- Testing
- risperidone, Sertindole
- Where
- Denmark
- Volunteers
- 1 people, healthy volunteers welcome
- Sponsor
- Birte Glenthoj
Parkinson's Disease
An Observational Study on Safinamide, Rasagiline and Other Standard of Care in PD
The purpose of this study is to evaluate how safinamide, rasagiline and other SoC drugs are associated with the quality of life of PD patients by means of the Parkinson's Disease Questionnaire (PDQ)-39 items.
- Trial name
- SUCCESS (NCT03994328)
- Where
- 3 sites in Germany, Italy and 1 more
- Volunteers
- 1,235 people
- Sponsor
- Zambon SpA
Stigmatization
The Impact of Acceptance and Commitment Therapy on Stigmatization
The goal of study is to determine the effect of acceptance and commitment therapy-based psychoeducation on the level of stigmatization applied to relatives of schizophrenia patients.
- Trial name
- NCT06368011
- Testing
- acceptance and commitment therapy
- Where
- Turkey (Türkiye)
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Mustafa Kemal University
Leukemia, Myelodysplastic Syndromes
Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With Advanced Myeloid Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining monoclonal antibody therapy with chemotherapy may kill more cancer cells.
- Conditions
- Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
- Trial name
- NCT00014495
- Testing
- filgrastim, cytarabine, bismuth Bi213 monoclonal antibody M195
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Ovarian Cancer, Solid Tumors
A Study of TAK-853 in Adult Participants With Folate Receptor Alpha-Positive Advanced Ovarian Cancer And Other Solid Tumors
The main aim of this study are to check for side effects from TAK-853, check how much TAK-853 participants can receive without getting side effects from it, check how well TAK-853 controls symptoms, and to check how much TAK-853…
- Trial name
- NCT06390995
- Testing
- TAK-853
- Where
- 20 sites in Japan
- Volunteers
- 28 people
- Sponsor
- Takeda
Schizophrenia
Cognitive Behavioral Social Skills Training for Improving Social Functioning in People With Schizophrenia
This study evaluated the effectiveness of Cognitive Behavioral Social Skills Training versus goal-focused supportive contact in improving social functioning in people with schizophrenia.
- Trial name
- NCT00338975
- Testing
- Cognitive Behavioral Social Skills Training (CBSST), Goal-focused supportive contact (GFSC), Social Skills Training
- Where
- United States
- Volunteers
- 179 people
- Sponsor
- Veterans Medical Research Foundation
Diarrhea, Malnutrition, Other Nutritional Deficiencies
HIAS II - Study of Nutritional Supplementation in Hospitalized Children With Persistent Diarrhea or Malnutrition
This study will determine the effect of 7 days supplementation of alanyl-glutatime or glycine on the damaged intestinal barrier function on day 8 in children with persistent diarrhea or malnutrition.
- Trial name
- NCT00133562
- Testing
- Alanyl-glutamine, Glycine
- Volunteers
- 108 people
- Sponsor
- University of Virginia
Schizophrenia, Schizoaffective Disorder
Trial of Cognitive Behavioral Therapy for Schizophrenia
The following study addresses the hypothesis that cognitive-behavioral interventions will be effective in reducing positive and negative symptoms of schizophrenia under the conditions of the German health care system.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Delusional Disorder
- Trial name
- NCT00300651
- Testing
- Cognitive Behavioral Therapy
- Where
- Germany
- Volunteers
- 70 people
- Sponsor
- Philipps University Marburg
APS-related Hyperprolactinaemia, Schizophrenia
Changes in Hyperprolactinemia Secondary to Antipsychotics After Switching to Quetiapine
Hyperprolactinaemia is a common side effect of some antipsychotics (APS), including some atypicals. Clinical consequences of hyperprolactinaemia are broad including amenorrhea, galactorrhea, tender breasts, gynecomastia and…
- Conditions
- APS-related Hyperprolactinaemia, Schizophrenia, Bipolar Disorder
- Trial name
- NCT00952757
- Where
- 6 sites in Spain
- Volunteers
- 35 people
- Sponsor
- Investigaciones Médicas Montejo S.L.